Think.Health Ventures

Dr. Florian Kainzinger, the Managing Partner and Founder, leads investment decisions. He draws on over 20 years of healthcare management experience, including his prior role as CEO of Labor Berlin, where he ran a 500-employee diagnostic lab organization across 12 sites. The firm lists Dr. Michael Ruoff as Partner and Nils Bottler as Venture Partner, both with more than a decade of investment experience.

Think.Health Ventures functions as a specialized asset manager deploying its own capital alongside co-investors on a deal-by-deal basis. The firm maintains a network of individual investors and family offices who invest alongside it. It does not operate a traditional blind-pool fund with a fixed fund life, which gives it flexibility on deployment timing.

The firm targets early-stage and growth healthcare companies. Its website states typical investment sizes from €500,000 to €10 million. Portfolio companies span from seed-stage ventures to expansion-stage businesses across digital health, medical devices, diagnostics, and biotechnology.

Think.Health Ventures focuses exclusively on healthcare — spanning digital healthcare, medical technologies, health service providers, life sciences, pharmaceuticals, and biotechnology. The firm does not invest outside healthcare, and its portfolio reveals no exposure to generalist technology, consumer, or industrial sectors.

Deal flow appears concentrated in the DACH region — Germany, Austria, and Switzerland. Portfolio companies like Petleo, which supports over 1,000 veterinary practices across the DACH region and Luxembourg, reflect the firm's geographic center of gravity. The firm also backs select companies in broader Europe and the US, such as the California-based biotech startup Earli.

The firm operates exclusively through direct equity investments in healthcare companies. Its website lists no fund-of-funds commitments, and its co-investor model relies on bringing family offices and individual investors into specific deals rather than participating as a limited partner in third-party funds.

The firm actively brings in co-investors from its network of individual investors and family offices to participate alongside its own capital in specific deals. It does not present itself as a limited partner in external GP-led funds. Its model is to identify healthcare ventures, invest directly, and open the opportunity to aligned co-investors.